Leadership
Lurong Pan, PhD
Founder & CEO
MFE from UC Berkeley Haas School of Business, MS Artificial Intelligence (Georgia Tech), PhD Computational Biology (UAB) with structural biology postdoc. 18+ years in computational drug design across small molecule, protein, and RNA modalities. Senior Investigator at the Bill & Melinda Gates Foundation. Former Director & Senior Scientist at UAB Medicine. Founder & CEO of Ainnocence.
Kevin Chen, PhD
Chief Scientific Officer
Leads R&D strategy and moves Ainnocence's lead candidates forward across in-house therapeutic programs and external partnerships. 15+ years in biologics drug discovery across immuno-oncology, autoimmune disease, and neurodegeneration — advancing bispecific/multispecific antibodies, multifunctional fusion proteins, CAR-Ts, and blood-brain-barrier shuttle molecules from early discovery to IND. Formerly Executive Director and Head of Biologics at SciNeuro Pharmaceuticals (CNS-targeted biologics on BBB shuttle platforms), directed the preclinical pipeline from target ID through IND at Georgiamune, and held senior biologics leadership roles at OncoC4, NovaRock Biotherapeutics, and Precigen (Intrexon); co-founder and CTO of ElAb Bio. Inventor on 8 issued or pending patents; author of 10+ peer-reviewed papers in Blood, The Journal of Immunology, and Nature Immunology. PhD, Microbiology and Immunology, Medical University of South Carolina; BS, Veterinary Medicine, National Chung-Hsing University, Taiwan.
Core Team
Alejandra Martín
Senior Biologist
UC Davis (Biotechnology), pursuing dual masters in Molecular Biology and Bioinformatics. Former SRA/Scientist at Retro Biosciences (stem cell reprogramming, longevity research) and Sangamo Therapeutics (allogeneic cell therapies, Zinc Finger gene editing). Passionate about the convergence of biology, AI, and technology.
